ClinicalTrials.gg
CompletedNCT03071770Updated Jan 11, 2018

Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects

A Phase 1 interventional study of ivosidenib (AG-120) in Healthy, sponsored by Agios Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-11.

Sponsored by Agios Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2017, 9 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this Phase I, single-dose, open-label trial is to evaluate the pharmacokinetics and safety of ivosidenib (AG-120) in healthy, adult male Japanese and Caucasian subjects. The study plans to evaluate 3 cohorts of a single oral dose of ivosidenib (AG-120) in Japanese and Caucasian subjects. Pharmacokinetic sampling will take place serially through-out the duration of subject participation.

02

Conditions studied

  • Healthy

Keywords

  • Healthy Volunteers
  • Japanese
  • Caucasian
03

In context

Lead sponsor

Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Applicable to Japanese Subjects Only: Japanese subjects must have been born in Japan, have both parents and grandparents of Japanese origin, and not have lived outside of Japan for more than 5 years.
  • Applicable to Caucasian Subjects Only: Non-Japanese subjects must be Caucasian (ie, White) but may be of any ethnicity.
  • Healthy male subjects between 18 and 55 years of age (inclusive).
  • Provision of voluntary, written .
  • Capable of adhering to trial restrictions and examination schedules, in the opinion of the Investigator.
  • Must be able to communicate with the Investigator.
  • Must be in good health as determined by the Investigator according to past medical history, physical examination, vital signs, clinical laboratory test results, and ECGs.
  • Must have a (BMI) between 18 and 29 kg/m2 (inclusive), and body weight between 50-120kg.
  • Clinical laboratory test results (serum chemistry, hematology, and urinalysis) must be within normal limits or considered by the Investigator to be not after confirmation with the Agios Medical Monitor.
  • Vital signs (systolic and diastolic blood pressure, pulse rate, and oral body temperature) will be assessed in the supine position after the subject has rested for at least 5 minutes. Subject must be afebrile with vital signs within the following ranges at screening, Day -1 and pre dose: Systolic blood pressure: 90 to 140 mmHg; Diastolic blood pressure: 50 to 90 mmHg; Pulse rate: 40 to 110 bpm
  • Must have a normal or clinically acceptable 12-lead no later than Day -1. Subjects must have a pre-dose corrected for heart rate using Fridericia's formula (QTcF) value or average of 3 values, ≤450 msec. An ECG may be repeated once to determine subject eligibility after confirmation with the Agios Medical Monitor.
  • Subjects (with or without vasectomy) must agree to abstain from sexual intercourse or agree to the use of highly effective methods (at screening and throughout the course of the trial) and should avoid fathering a child during the course of the trial and for 90 days following the dose of the IMP. Subjects must refrain from sperm donations for the entire duration of the trial and for 90 days following the dose of AG 120.

Exclusion criteria

Exclusion Criteria:

  • Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from providing or participating in the trial in the opinion of the Investigator.
  • Any condition, including the presence of laboratory abnormalities, which places the subject at an unacceptable risk if he were to participate in the trial.
  • Recent history (within 3 years prior to dosing) of any neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, or other major disorder.
  • Use of any prescribed systemic or topical medication within 30 days or 5 terminal half-lives, whichever is longer, of IMP administration.
  • Exposure to an drug within 30 days prior to IMP administration or 5 half lives of that investigational drug, if known (whichever is longer).
  • Use of any non-prescribed systemic or topical medication (including vitamin/mineral supplements, and herbal medicines, eg, St. John's Wort) within 7 days of IMP administration.
  • Any surgical or medical condition that could affect drug absorption, distribution, metabolism, or excretion (eg, gastrectomy and cholecystectomy)
  • Subjects who plan to have any elective or medical procedures during the conduct of the trial (eg, dental procedure).
  • History of clinically significant multiple drug allergies (ie, 2 or more).
  • Any clinically significant allergic disease.
  • History of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual [DSM]) within 2 years prior to IMP administration, or positive drug screen test due to illicit drugs at any time prior to IMP administration during the screening period.
  • History of alcohol abuse within 2 years prior to IMP administration, or positive alcohol screen at any time prior to IMP administration during the screening period.
  • History of smoking within 3 months prior to IMP administration, or positive urine cotinine screen at any time prior to IMP administration during the screening period.
  • Known to have (HIV), hepatitis, or known to be a carrier of the surface antigen (HBsAg) or antibody (HCV Ab), or have positive results at screening.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    ivosidenib (AG-120)

    Drug: ivosidenib (AG-120)

Interventions

  • A single-dose of ivosidenib (AG-120) administered in healthy Japanese and Caucasian subjects

06

What researchers measure

Primary outcomes

  1. AUC

    AG-120 Area Under the Curve

    Time frame: Pharmacokinetic sampling for ivosidenib (AG-120) will be taken for 504 hours (21 days) after single dose

  2. Cmax

    AG-120 Maximum Plasma Concentration

    Time frame: Pharmacokinetic sampling for ivosidenib (AG-120) will be taken for 504 hours (21 days) after single dose

Secondary outcomes

  1. Incidence of Adverse Events

    Assessment of adverse events

    Time frame: 28 days after single-dose ivosidenib (AG-120)

07

Study locations

1 site
  • West Coast Clinical Trial (WCCT)
    Cypress, California 90630, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in May 2017, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2017
First posted
Mar 7, 2017
StartActual
Mar 31, 2017
Primary completionActual
May 9, 2017
CompletionActual
Sep 6, 2017
Last update
Jan 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03071770
Responsible party
Sponsor
First posted
Mar 7, 2017
Start date
Mar 31, 2017
Primary completion
May 9, 2017
Completion
Sep 6, 2017
Last update
Jan 11, 2018

Study contacts

Medical Affairs Agios Pharmaceuticals, Inc
study chair · Agios Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivosidenib

Start the discussion